BUSINESSGUARDIAN US
Ozempic maker Novo Nordisk sues US rival over ‘materially misleading’ ads
Novo Nordisk is suing Eli Lilly over 'false and materially misleading' advertisements for its weight-loss and anti-diabetes treatments. The Danish pharmaceutical company alleges Eli Lilly is using outdated trial data to compare its highest doses against lower doses of Novo Nordisk's medicines.
Mentioned
Related Signal
Adjacent reporting
- Novo Nordisk is suing Eli Lilly over ads it says mislead consumers on weight loss drug efficacy
- Novo Nordisk sues Eli Lilly, accusing it of false advertising
- Novo Nordisk sues Eli Lilly over ads comparing GLP-1 medications
- STAT+: Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’
- Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising